Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Frailty × cabozantinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 28 Carcinoma, Hepatocellular 15 Prostatic Neoplasms 11 Neoplasm Metastasis 11 Carcinoma, Non-Small-Cell Lung 7 Neoplasms 6 Brain Neoplasms 6 Sarcoma 5 Neuroendocrine Tumors 5 Urinary Bladder Neoplasms 4 Melanoma 4 Kidney Neoplasms 4 Carcinoma, Transitional Cell 4 Breast Neoplasms 4 Recurrence 3 Pancreatic Neoplasms 3 Osteosarcoma 3 Lung Neoplasms 3 Clear-cell metastatic renal cell carcinoma 3 Adenocarcinoma 3 Uterine Cervical Neoplasms 2 Thyroid Diseases 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Sarcoma, Ewing 2 Glioma 2 Glioblastoma 2 Colorectal Neoplasms 2 Carcinoma, Squamous Cell 2 Carcinoma, Neuroendocrine 2

Interventions

peflavit 1 microcrystalline cellulose 1 fisetin 1 epigallocatechin gallate 1 cabozantinib 1 Temozolomide 1 Quercetin 1 Protons 1 Photons 1 Flavonoids 1 Dasatinib 1 Ascorbic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04134390 2024-01-09

CABOMAYOR

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

Frailty, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡